

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1509)

**DECISION OF THE LISTING COMMITTEE
FOR THE CANCELLATION OF LISTING
AND
REVIEW REQUEST OF THE DELISTING DECISION**

This announcement is made by Harmonicare Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (1) the announcement of the Company dated 28 March 2019 in relation to its delay in the publication of the 2018 Annual Results and despatch of the 2018 Annual Report, (2) the announcement of the Company dated 7 May 2019 in relation to its publication of unaudited management accounts for the year ended 31 December 2018 and the engagement of its Internal Control Consultant, (3) the announcement of the Company dated 12 June 2019 in relation to the guidance received from the Stock Exchange regarding the resumption of trading of the Company’s shares on the Stock Exchange, (4) the quarterly update announcement of the Company dated 28 June 2019 in relation to, among others, its resumption progress, (5) the update announcement of the Company dated 31 July 2019 in relation to the progress of its internal control review, (6) the announcement of the Company dated 30 August 2019 in relation to, among others, further delay in publication of the 2018 Annual Results and the delay in publication of the 2019 Interim Results, (7) the quarterly update announcement of the Company dated 29 September 2019 in relation to, among others, its resumption progress, (8) the quarterly update announcement of the Company dated 24 December 2019 in relation to, among others, its resumption progress, (9) the voluntary announcement of the Company dated 10 March 2020 on the impact of novel coronavirus (COVID-19) epidemic on the Group’s business operations, (10) the supplemental announcement of the Company dated 25 March 2020 on the results of its internal control review, (11) the quarterly update announcement of the Company dated 31 March 2020 in relation to, among others, its resumption progress, (12) the announcement of the Company dated 15 June 2020 in relation to, among others, the cessation of construction of a subsidiary, (13) the quarterly update announcement of the Company dated 30 June 2020 in relation to, among others, its resumption progress, (14) the update announcement of the Company dated 17 July 2020 in relation to the progress of its internal control review and (15) the quarterly update announcement of the Company dated 30 September 2020 in relation to, among others, its resumption progress (the “**Quarterly Update Announcement**”). Capitalised terms used herein shall have the same meanings as those defined in the Quarterly Update Announcement unless otherwise stated herein.

BACKGROUND

Trading in the Shares have been suspended with effect from 9:00 a.m. on 1 April 2019 and will remain suspended pending fulfilment of the resumption guidance from the Stock Exchange and any supplement or modification thereto. The period for the Company to resume trading has expired on 30 September 2020 under Rule 6.01A(1) of the Listing Rules.

LISTING COMMITTEE HEARING AND DECISION ON CANCELLATION OF LISTING

On 26 November 2020, the Listing Committee of the Stock Exchange (the “**Listing Committee**”) considered the Company’s resumption and listing status. The Company received a letter (the “**Letter**”) from the Stock Exchange dated 27 November 2020 stating that the Listing Committee has decided to cancel the Company’s listing under Rule 6.01A of the Listing Rules (the “**Delisting Decision**”).

It is indicated in the Letter that unless the Company applies for a review of the Delisting Decision pursuant to Chapter 2B of the Listing Rules, the last day of listing of the Shares would be on 11 December 2020, and the listing of the Shares would be cancelled with effect from 9:00 a.m. on 14 December 2020.

SUBMISSION OF REVIEW REQUEST

After seeking professional advice and with due consideration, the Company has submitted an application requesting the Delisting Decision be referred to the Listing Review Committee for review pursuant to Chapter 2B of the Listing Rules (the “**LRC Review**”). The Company hereby reminds its shareholders (the “**Shareholders**”) and potential investors that the outcome of the LRC Review is uncertain. Shareholders who have any queries about the implications of the delisting of the Shares are advised to seek appropriate professional advice.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the Shares on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2019. Trading in the Shares will remain suspended until further notice.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Harmonicare Medical Holdings Limited
Lin Yuming
Chairman, Executive Director and President

Hong Kong, 4 December 2020

As at the date of this announcement, the executive directors of the Company are Mr. Lin Yuming, Mr. Yang Guo and Mr. Wei Rongda; the non-executive directors of the Company are Mr. Lin Yuguo, Mr. Qiu Jianwei and Mr. Xu Jun; and the independent non-executive directors of the Company are Ms. Fang Lan, Mr. Cai Jiangnan and Ms. Hsu Wai Man Helen.